ReviewMycoses2025
Candida vulturna, the Next Fungal Menace? A Narrative Review.
Review in Mycoses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Short tandem repeat genotyping of Pichia kudriavzevii isolates reveals long-standing clinical clade with high transmission potential.Medical mycology · 2026Article
- Silent Outbreaks ofAntibiotics (Basel, Switzerland) · 2026Article
- Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe yeast Candida vulturna is a member of the Candida haemulonii species complex, like its close relative Candida auris. Members of this species complex, including C. vulturna, often display reduced susceptibility to one or more antifungal classes. Human invasive infections by C. vulturna are increasingly reported in various countries, while the first identification of this fungus, isolated from a flower, occurred less than 10 years ago. The purpose of this review is to compile all reported outbreaks and cases and describe the characteristics of this emerging yeast.
methodsPubMed, Scopus, Web of Science and Google Scholar were reviewed for publications until April 14, 2025. Records in English were found by using the keyword Candida (Candidozyma) vulturna, and were included if cases were invasive infections.
resultsAll reported 94 cases were exclusively from the last 10 years, often in Asian or Latin American countries and included three outbreaks in Brazil, Vietnam and China. Patients displayed diverse clinical characteristics with an overall low mortality rate of 18%. Most studies (n = 11) performed antifungal susceptibility testing (AFST) with microbroth dilution methods and found reduced susceptibility to azoles and amphotericin B. The ERG11
conclusionAlthough C. vulturna is still a rare yeast, cases are increasingly reported in tropical regions. The yeast has outbreak potential, in addition to reduced susceptibility to azoles and amphotericin B. Treatment with echinocandins showed favourable outcomes with a low mortality rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.